ArticleCell2020
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 480 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 2 pooled it
46.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
480 citing papers in PubMed, 2 syntheses or guidelines pooled it, 729 citations in OpenAlex.
- Impact of body composition on clinical outcomes in patients with hepatocellular carcinoma: A systematic review and meta-analysis.Hepatology communications · 2026Pooled it
- Mechanisms underlying obesity-malignancy connection: a systematic narrative review.Journal of physiology and biochemistry · 2025Pooled it
- Significance of GSH and HRedox report : communications in free radical research · 2026Review
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer.Annals of medicine · 2026Article
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.Nature immunology · 2026Article
- AI-derived 3D body composition predicts prognosis of chemoimmunotherapy in small cell lung cancer: a multicenter study.Journal for immunotherapy of cancer · 2026Article
- Host metadherin coordinates hepatic lipid metabolism and CD8Cell metabolism · 2026Article
- Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Preoperative CA125 and metabolic factors associated with high-risk pathology in endometrial cancer.Oncology letters · 2026Article
- Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas.Cancer discovery · 2026Article
- ZBP1-mediated Treg cell dysfunction exacerbates neuroimmune dysregulation in Alzheimer's disease under metabolic stress.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- A Review of the Relationship Between Obesity and Immunotherapy Response in Cancer.International journal of molecular sciences · 2026Review
- Metabolic Targeting of SREBP1 Reprograms the Obesity-Driven Ascites Immune Microenvironment and Enhances Chemotherapy Response in Obesity-Associated Ovarian Cancer.bioRxiv : the preprint server for biology · 2026Article
- Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.European heart journal · 2026Review
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Energy Balance-Related Factors and Direct Tumor-Adipocyte Contact in Colorectal Cancer: Etiologic Insights from the Population-Based Netherlands Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Article
- Metabolic and Inflammatory Risk Stratification in Resected Cholangiocarcinoma: A Retrospective Exploratory Analysis.Medical sciences (Basel, Switzerland) · 2026Article
420 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 5 institutions in 2 countries.
Alison E RingelDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Jefte M DrijversDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Gregory J BakerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Alessia CatozziDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA.
Juan C García-CañaverasDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA; Biomarkers and Precision Medicine Unit, Instituto de Investigación Sanitaria Fundación Hospital La Fe, València 46026, Spain.
Brandon M GassawayDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Brian C MillerDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Vikram R JunejaDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Thao H NguyenDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Shakchhi JoshiDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Cong-Hui YaoDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Haejin YoonDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Peter T SageDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Justin D TrombleyDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Connor A JacobsonLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Zoltan MaligaLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Steven P GygiDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Joshua D RabinowitzDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA; Biomarkers and Precision Medicine Unit, Instituto de Investigación Sanitaria Fundación Hospital La Fe, València 46026, Spain.
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: arlene_sharpe@hms.harvard.edu.
Marcia C HaigisDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: marcia_haigis@hms.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USPrinceton University · USBoston VA Research Institute · USCenter for Systems Biology · US
Funding
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MMolecular mechanisms of Nutrient sensing in cancerR01CA213062 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2017 to 2021
$1.9MControl of metabolic homeostasis in diabetes by sirtuinsR01DK103295 · NIDDK · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2015 to 2018
$1.5MTargeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer MutationsK08CA248960 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILLER, BRIAN C · 2020 to 2024
$1.2MMetabolic regulation of anti-tumor T cell responsesF31CA224601 · NCI · HARVARD MEDICAL SCHOOL · PI DRIJVERS, JEFTE M. · 2018 to 2020
$98kNCI NIH HHS F31 CA224601NCI NIH HHS K08 CA248960NCI NIH HHS R01 CA213062NCI NIH HHS T32 CA207021NCI NIH HHS U54 CA225088NIAID NIH HHS P01 AI056299NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK103295NIDDK NIH HHS U24 DK059637
Abstract
Obesity is a major cancer risk factor, but how differences in systemic metabolism change the tumor microenvironment (TME) and impact anti-tumor immunity is not understood. Here, we demonstrate that high-fat diet (HFD)-induced obesity impairs CD8
Indexed as
ImmunityTumor MicroenvironmentAdiposityAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationDiet, High-FatFatty AcidsHEK293 CellsHumansHypoxia-Inducible Factor-Proline DioxygenasesKineticsLymphocytes, Tumor-InfiltratingMice, Inbred C57BLMice, KnockoutEGLN3 protein, humanFatty AcidsHypoxia-Inducible Factor-Proline DioxygenasesPHD3 protein, mouseProcollagen-Proline Dioxygenaseanti-tumor immunityCD8+ T cellscolorectal cancerfat oxidationmetabolismobesitytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.